Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes

Circulation

Volumn 99, Issue 6, 1999, Pages 817-822

  Matoba, Satoaki ^b   Tatsumi, Tetsuya ^a   Keira, Natsuya ^b   Kawahara, Akira ^b   Akashi, Kazuko ^b   Kobara, Miyuki ^b   Asayama, Jun ^a   Nakagawa, Masao ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Kyoto Pref University of Medicine ^*

Author keywords

Angiotensin; Bradykinin; Hypoxia; Myocytes; Nitric oxide

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINOGUANIDINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; CANDESARTAN; CILAZAPRILAT; CREATINE KINASE; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GUANYLATE CYCLASE INHIBITOR; ICATIBANT; INDOMETACIN; METHYLENE BLUE; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE C INHIBITOR; STAUROSPORINE;

ANIMAL CELL; ARTICLE; CELL HYPOXIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART PROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; REOXYGENATION;

EID: 0032934154     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.6.817     Document Type: Article

References (35)

1. Linz W, Schölkens BA, Han Y-F. Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. J Cardiovasc Pharmacol. 1986;8(suppl 10):S91-S99.
2. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer ,H, Hawkins CM, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. N Engl J Med. 1992;327:669-677.
3. Ball SG, Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
4. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation. 1988;77(suppl 1):I-4-I-13.
5. Tan L-B, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ Res. 1991;69:1185-1195.
6. Kitakaze M, Minamino T, Node K, Komamura K, Shinozaki Y, Mori H, Kosaka H, Inoue M, Hori M, Kamada T. Beneficial effects of inhibition angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation. 1995;92:950-961.
7. Hartman JC. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. Ann Thorac Surg. 1995;60:789-792.
8. Liu Y-H, Yang X-P, Sharov VG, Sigmon DH, Sabbah HN, Carretero OA. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension. 1996;27:7-13.
9. Linz W, Wiemer G, Schölkens BA. Role of kinins in the pathophysiology of myocardial ischemia: in vitro and in vivo studies. Diabetes. 1996; 45(suppl 1):S51-S58.
10. Goshima K. Ouabain-induced arrhythmias of single isolated myocardial cells and cell clusters cultured in vitro and their improvement by quinidine. J Mol Cell Cardiol. 1977;9:7-23.
11. Sadoshima J, Jahn L, Takahashi T, Kulik TJ, Izumo S. Molecular characterization of stretch-induced adaptation of cultured cardiac cells. J Biol Chem. 1992;267:10551-10560.
12. McGuire PG, Orkin RW. Methods in laboratory investigation isolation of rat aortic endothelial cells by primary explant techniques and their phenotypic modulation by defined substrata. Lab Invest. 1987;57:94-105.
13. Tatsumi T, Matoba S, Kobara M, Keira N, Kawahara A, Tsuruyama K, Tanaka T, Katamura M, Nakagawa C, Ohta B, Yamahara Y, Asayama J, Nakagawa M. Energy metabolism after ischemic preconditioning in streptozotocin-induced diabetic rat hearts. J Am Coll Cardiol. 1998;31:707-715.
14. Mashford ML, Roberts ML. Determination of blood kinin levels by radioimmunoassay. Biochem Pharmacol. 1972;21:2727-2735.
15. Honma M, Satoh T, Takezawa J, Ui M. An ultra sensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small volume samples from blood and tissue. Biochem Med. 1977;18:257-273.
16. Asayama J, Yamahara Y, Ohta B, Miyazaki H, Tatsumi T, Matsumoto T, Inoue D, Nakagawa M. Release kinetics of cardiac troponin T in coronary effluent from isolated rat hearts during hypoxia and reoxygenation. Basic Res Cardiol. 1992;87:428-436.
17. Yoshiyama M, Kim S, Yamagishi H, Omura T, Tani T, Yanagi S, Toda I, Teragaki M, Akioka K, Takeuchi K, Takeda T. Cardioprotective effect on the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J. 1994;128:1-6.
18. Nolly H, Carbini LA, Scicli G, Carretero OA, Scicli AG. A local kinin-kallikrein system is present in rat hearts. Hypertension. 1994;23:919-923.
19. Baumgarten CR, Linz W, Kunkel G, Schölkens BA, Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol. 1993;108:293-295.
20. Wiemer G, Schölkens BA, Linz W. Endothelial protection by converting enzyme inhibitors. Cardiovasc Res. 1994;28:166-172.
21. 2 receptors in adult myocardium and neonatal rat cardiomyocytes. Circ Res. 1995;76:773-780.
22. 2 receptor stimulation is calcium-independent. J Biol Chem. 1986;261:3831-3837.
23. ++-dynamics in endothelial cells. Am J Physiol. 1987;253:C588-C598.
24. Revtyak GE, Buja LM, Chien KR, Campbell WB. Reduced arachidonate metabolism in ATP-depleted myocardial cells occurs early in cell injury. Am J Physiol. 1990;259:H582-H591.
25. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide-physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
26. Schrör K. Role of prostaglandins in the cardiovascular effects of bradykinin and angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol. 1992;20(suppl 9):S68-S73.
27. Vuorinen P, Laustiola K, Metsa-Ketela T. The effects of cyclic AMP and cyclic GMP on redox state and energy state in hypoxic rat atria. Life Sci. 1984;35:155-161.
28. Wahler GM, Sperelakis N. Intracellular injection of cyclic GMP depresses cardiac slow action potentials. J Cyclic Nucleotide Protein Phosphorylation Res. 1985;10:83-95.
29. Fischmeister R, Hartzell HC. Cyclic guanosine 3′,5′-monophosphate regulates the calcium current in single cells from frog ventricle. J Physiol (Lond). 1987;387:453-472.
30. Wahler GM, Rusch NJ, Sperelakis N. 8-Bromo-cyclic GMP inhibits the calcium current in embryonic chick ventricular myocytes. Can J Physiol Pharmacol. 1989;68:531-534.
31. 2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci U S A. 1991;88:1197-1201.
32. Shah AM, Spurgeon HA, Sollott SJ, Talo A, Lakatta EG. 8-Bromo cGMP reduces the myofilament response to calcium in intact cardiac myocytes. Circ Res. 1994;74:970-978.
33. Balligand JL, Kelly RA, Marsden PA, Smith TW, Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA. 1993;90:347-351.
34. Brady AJ, Warren JB, Poole-Wilson PA, Williams TJ, Harding SE. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol. 1993;265:H176-H182.
35. Maulik N, Engelman DT, Watanabe M, Engelman RM, Rousou JA, Flack JE III, Deaton DW, Gorbunov NV, Elsayed NM, Kagan VE, Das DK. Nitric oxide/carbon monoxide: a molecular switch for myocardial preservation during ischemia. Circulation. 1996;94(suppl II):II-398-II-406.